Piramal completes Phase-I trials of new cancer molecule
Piramal Healthcare today said it has completed the first phase of clinical trials of a new oral drug for treating cancer and will move to the next stage of development.
Written By Miscellaneous|Last Updated: May 22, 2012, 05:16 PM IST|Source: Exclusive
New Delhi: Piramal Healthcare today said it has completed the first phase of clinical trials of a new oral drug for treating cancer and will move to the next stage of development.
The company said it has established safety, apart from determining maximum tolerated dosages in humans for its new molecule code named P1446A-05 in multi-centric Phase-I trials conducted in India and Canada.
"We are extremely pleased with the results of the P1446A -05 and are committed to moving the molecule further in clinical development for the treatment of cancer," Piramal Healthcare Director Swati Piramal said in a statement.
The data of the Phase-I trials will be presented at the annual meeting of American Society for Clinical Oncology to be held in Chicago from June 1-5 this year, the company said.
The results of trials conducted in India and Canada, each investigating two different dosing schedules, will be reported in the meeting, it added.
"The completion of these two phase I studies readies P1446A-05...To enter into a broader context of clinical development across a spectrum of malignant diseases. It offers continuous exposure to the targets and has a profile that can be integrated with other therapies," Piramal Healthcare Executive Vice-President Clinical Research Alan Hatfield said.
Phase I clinical trials are conducted on a limited small number of human beings to establish safety, efficacy and check side effects on new drug molecules.
P1446A-05 exhibits high oral bio-availability, shows potent anti-proliferative activity in several human cancer cells and is efficacious in xenograft tumour models, Piramal Healthcare claimed.
The company further said: "P1446A-05 will be the second molecule in Piramal`s oncology pipeline to enter Phase-II trials (conducted on a larger human sample)."
The first molecule P276 in in Phase II/III trials for multiple indications of cancer, it added.
Piramal Healthcare scrips were trading at Rs 420 per share in the afternoon trade on BSE, down 0.05 per cent from the previous close.
PTI
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookies Setting
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device and the processing of information obtained via those cookies (including about your preferences, device and online activity) by us and our commercial partners to enhance site navigation, personalise ads, analyze site usage, and assist in our marketing efforts. More information can be found in our Cookies and Privacy Policy. You can amend your cookie settings to reject non-essential cookies by clicking Cookie Settings below.
Manage Consent Preferences
Strictly Necessary Cookies
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work or you may not be able to login.
Functional Cookies
These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.
Targeting Cookies
These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They are also used to limit the number of times you see an advert as well as help measure the effectiveness of an advertising campaign. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.
Performance Cookies
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we may not know when you have visited our site, and may not be able to monitor its performance.